ASK1 anticorps
-
- Antigène Voir toutes ASK1 (MAP3K5) Anticorps
- ASK1 (MAP3K5) (Mitogen-Activated Protein Kinase Kinase Kinase 5 (MAP3K5))
-
Reactivité
- Humain, Souris
-
Hôte
- Lapin
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp ASK1 est non-conjugé
-
Application
- Western Blotting (WB), Immunohistochemistry (IHC), Flow Cytometry (FACS), Immunocytochemistry (ICC)
- Attributs du produit
- Expected molecular weight of target: 1374 kDa
- Purification
- Affinity purification
- Isotype
- IgG
- Top Product
- Discover our top product MAP3K5 Anticorps primaire
-
-
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1 mg/mL
- Buffer
- PBS with 0.02 % sodium azide, 50 % glycerol, pH 7.4
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- WARNING: Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.
- Conseil sur la manipulation
- Avoid repeated freeze/thaw cycles.
- Stock
- -20 °C
-
- Antigène
- ASK1 (MAP3K5) (Mitogen-Activated Protein Kinase Kinase Kinase 5 (MAP3K5))
- Autre désignation
- MEKK5 (MAP3K5 Produits)
- Synonymes
- anticorps ASK1, anticorps MAPKKK5, anticorps MEKK5, anticorps mitogen-activated protein kinase kinase kinase 5, anticorps MUD21.11, anticorps MUD21_11, anticorps 7420452D20Rik, anticorps ASK, anticorps Mekk5, anticorps Ask1, anticorps RGD1306565, anticorps mitogen-activated protein kinase kinase kinase 5, anticorps MAP3K5, anticorps MAPKKK5, anticorps Map3k5, anticorps map3k5
- ID gène
- 4217
- UniProt
- Q99683
- Pathways
- Signalisation MAPK, Positive Regulation of Endopeptidase Activity, Unfolded Protein Response
-